Literature DB >> 10073600

Prominence of cell-mediated immunity effectors in "pauci-immune" glomerulonephritis.

M A Cunningham1, X R Huang, J P Dowling, P G Tipping, S R Holdsworth.   

Abstract

The majority of patients with rapidly progressive crescentic glomerulonephritis show histologic features of extensive necrosis and focal and segmental proliferation with fibrin production, but little or absent Ig deposition in the glomerulus. This subcategory of the disease, labeled "pauci-immune" glomerulonephritis, has recently been shown to be associated with the presence of antineutrophil cytoplasmic antibody in the patient's circulation (but not within the glomerulus). The absence of the effectors of humoral immunity at the site of renal injury led to this investigation of the contribution of cell-mediated immunity to the glomerular injury in this form of glomerulonephritis. In 15 patients presenting acutely with pauci-immune glomerulonephritis, CD3-positive T cells (3.7+/-2.5 [mean +/- SD] cells per glomerular cross section, [c/gcs]), CD45RO-positive T cells (2.7+/-1.9 c/cgs), macrophages (7.3+/-6.1 c/gcs), fibrin (3+), and endothelial-associated tissue factor were demonstrated to be prominent in glomeruli. These mediators were absent in a group of 12 patients with thin basement membrane disease and only occasionally observed in a group of eight patients with "humorally mediated"(noncrescentic) glomerulonephritis. Thus, in pauci-immune glomerulonephritis, there is the development of significant cell-mediated immunity with activated T cells, macrophages, tissue factor, and fibrin at the site of glomerular injury, suggesting that this glomerular disease is most likely a manifestation of T cell-directed cognate immune injury.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073600     DOI: 10.1681/ASN.V103499

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  39 in total

Review 1.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Th2 dominance in nasal mucosa in patients with Wegener's granulomatosis.

Authors:  C E Balding; A J Howie; A B Drake-Lee; C O Savage
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

3.  CD4(+) T cells specific to a glomerular basement membrane antigen mediate glomerulonephritis.

Authors:  Jean Wu; John Hicks; Jason Borillo; William F Glass; Ya-Huan Lou
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

4.  What sensitized cells just might be doing in glomerulonephritis.

Authors:  W Kline Bolton
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

Review 5.  Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides.

Authors:  P Lamprecht
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

Review 6.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

Review 7.  Leukocytes in glomerular injury.

Authors:  Stephen R Holdsworth; Peter G Tipping
Journal:  Semin Immunopathol       Date:  2007-10-16       Impact factor: 9.623

8.  Renal participation of myeloperoxidase in antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis.

Authors:  Kim M O'Sullivan; Camden Y Lo; Shaun A Summers; Kirstin D Elgass; Paul J McMillan; Anthony Longano; Sharon L Ford; Poh-Yi Gan; Peter G Kerr; A Richard Kitching; Stephen R Holdsworth
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

9.  Granulomatous transformation of capillary lesions in pulmonary-renal syndrome autologously induced anti-glomerular basement membrane disease in Wistar-Kyoto rats.

Authors:  Daiju Aoyagi; Koh Nakazawa; Tomoki Kaneyama; Junya Masumoto; Masako Otani; Hidekazu Shigematsu
Journal:  Clin Exp Nephrol       Date:  2010-01-09       Impact factor: 2.801

10.  Management of ANCA-associated vasculitis: Current trends and future prospects.

Authors:  Sally Hamour; Alan D Salama; Charles D Pusey
Journal:  Ther Clin Risk Manag       Date:  2010-06-24       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.